Play of the Day – ANIX

Can we beat yesterday’s home run?                                                                                                                                                                                                                                                                                                                                                                                                                 March 20, 2024 Play of the Day – ANIX Can we beat yesterday’s home run? *Sponsored by Sica Media Multiple Timeframes Suggest NOW is the Time to Start Watching ANIX for the Next Move Coming hot off the heels of a massive alert already this week, I am excited to share my latest idea with you this morning. As you know, small biotech companies have really been in the market’s focus lately, so I have been digging in that sector for another great stock that could be ready to move. Well, this one looks absolutely primed and ready to go! Pull up Anixa Biosciences (ANIX) on your platform right now and take a look. Since this one is already on the move, I think time is of the essence.  Today could be a crucial day for the stock. First, I want you to get a bigger picture and look at the daily chart, which is below… What is important here is that shortly after ANIX started to trade back above the 20-day, it switched gears from a downtrend into an uptrend. ANIX went on to make a bull run 60% higher following that. Now, for whatever reason, the stock sold off all the way back to where it was before that big run, and for me, it is just a waiting game for when the next spark could drive it higher again. I think NOW is the ideal time to look at ANIX. When you zoom into the hourly chart (my favorite for swing trading), you’ll see that ANIX has just started to break back into a bullish trend. We can see that twice in the last few days, with stock switching to an uptrend (blue candles) and also two great “GO” signals. ✅ As you can see, ANIX is already on the move, so I think it is really important for you to start watching this one as soon as you can. If I’m right, I think this will be another great lesson in reading technical charts. If things go well, it might dwarf yesterday’s big winner, which would be really fun to see! It’s always more exciting to see things unfold live during the day rather than read the highlights of what happened the next day… so make sure you don’t miss out on this today. I always like seeing that insiders are not shy to put their own money to work. We saw the CEO and a director make [significant moves]( just last week. Maybe they see the same thing I do at these levels. On the business side of things, Anixa Biosciences Inc (ANIX) is a clinical-stage biotech company that focuses on the treatment and prevention of cancer. You read that correctly. This is one of the only companies I’ve come across that’s actually trying to prevent cancer, not cure it. Big difference there. More on that in a moment… The company has partnered with oncology heavyweights such as Moffitt Cancer Center and the Cleveland Clinic, and has received both funding and collaboration from the National Cancer Institute. This collaborative approach has allowed ANIX to explore its therapies with considerably lower overhead, especially considering how novel and sophisticated those therapies are. The company [reports]( an annual cash burn of under $6 million annually since 2017, but as of October 31, 2023, it had a war chest of $24 million. If they can maintain that cash burn, that’s a massive [cash runway](. On the treatment side of things, ANIX is developing a unique CAR-T therapy (you can read all about these on the company’s website [here]( with Moffitt that targets receptors that in healthy women appear only on the ovaries. The idea is to train the immune systems of women with ovarian cancer to target those cells since the ovaries are not vital organs. Interestingly, according to the company, while that receptor “does not exist on cells in healthy adults except for ovaries in women and testes in men, it does appear on blood vessels that nourish other tumors. Therefore, should this therapy work for ovarian cancer patients, it may also work for multiple other cancers.” [emphasis added] If it pans out, the company believes its “proprietary (patented) approach could be one of the first, if not the first, effective CAR-T therapy for a solid tumor.” On the prevention side, ANIX is developing cancer vaccines. The idea sounds far-fetched, but once you look into the technology, it sounds extremely promising. In brief, the company is working with the Cleveland Clinic on vaccines that would prevent breast cancer — especially the most lethal form, triple-negative breast cancer (TNBC) — and ovarian cancer. The vaccines would work by training the immune system to target “retired” proteins for destruction. The breast cancer vaccine would target the protein alpha-lactalbumin, which is present in healthy breast tissue only when a woman is lactating. Critically, it is also present in many types of breast cancer, especially TNBC. The idea would be to give women — especially those with breast cancer gene mutations — the vaccine after menopause, thus heading off breast cancer before it can form. In mice studies, Cleveland Clinic researchers found that “vaccination against alpha-lactalbumin completely prevented breast cancer” in mice that were genetically disposed to getting it, compared to an 80% breast cancer prevalence in control-group mice. The company is pursuing a similar strategy for ovarian cancer, but targeting something called the anti-Mullerian hormone receptor II (AMHR2-ED). In animal models, Cleveland Clinic researchers found that “vaccination against the extracellular domain of [AMHR2-ED] significantly inhibits tumor growth and enhances overall survival.” According to the company, “the results indicate that vaccinating women against AMHR2-ED could provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer.” There is a lot going on here, so poke around on Google to see what you find to do your own due diligence, and of course, always approach your trading in a responsible manner. Never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration. Just because something happened in the past, doesn’t necessarily mean it will happen again. Bottom line: When it comes to the stock chart, I think that ANIX is at an inflection point for a short-term move right now. I don’t know how long the current setup will look as attractive as it does right now, so make sure you start watching it right away. To Your Success, 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull DISCLAIMERS *PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising Anixa Biosciences, Inc from a period beginning on for a one day marketing program. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Anixa Biosciences, Inc, increased trading volume, and possibly an increased share price of Anixa Biosciences, Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Anixa Biosciences, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 2024 Bright Ideas newsletter 62 Calef Hwy. #233 lee, NH 03861, United States of America